{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:41:38Z","timestamp":1782823298141,"version":"3.54.5"},"reference-count":89,"publisher":"Medknow","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,13]],"date-time":"2013-12-13T00:00:00Z","timestamp":1386892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["saudiophthaljournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Journal of Ophthalmology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.sjopt.2013.12.003","type":"journal-article","created":{"date-parts":[[2013,12,14]],"date-time":"2013-12-14T17:45:12Z","timestamp":1387043112000},"page":"19-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Recent developments on dry eye disease treatment compounds"],"prefix":"10.4103","volume":"28","author":[{"given":"Basilio","family":"Colligris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan Awad","family":"Alkozi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Pintor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2581","reference":[{"issue":"1","key":"10.1016\/j.sjopt.2013.12.003_b0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/09286580802228509","article-title":"Prevalence of and associated factors for dry eye in a Spanish adult population (the Salnes Eye Study)","volume":"16","author":"Viso","year":"2009","journal-title":"Ophthalmic Epidemiol"},{"issue":"8","key":"10.1016\/j.sjopt.2013.12.003_b0010","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/OPX.0b013e318181a947","article-title":"Long-term incidence of dry eye in an older population","volume":"85","author":"Moss","year":"2008","journal-title":"Optom Vis Sci"},{"issue":"4","key":"10.1016\/j.sjopt.2013.12.003_b0015","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1834-7819.2005.tb00363.x","article-title":"Burning mouth syndrome: an update on recent findings","volume":"50","author":"Barker","year":"2005","journal-title":"Aust Dent J"},{"issue":"9","key":"10.1016\/j.sjopt.2013.12.003_b0020","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1111\/j.1743-6109.2009.01369.x","article-title":"Vaginal dryness: a comparison of prevalence and interventions in 11 countries","volume":"6","author":"Leiblum","year":"2009","journal-title":"J Sex Med"},{"issue":"3","key":"10.1016\/j.sjopt.2013.12.003_b0025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.preteyeres.2009.04.003","article-title":"Neural regulation of lacrimal gland secretory processes: relevance in dry eye diseases","volume":"28","author":"Dartt","year":"2009","journal-title":"Prog Retin Eye Res"},{"issue":"7","key":"10.1016\/j.sjopt.2013.12.003_b0030","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1167\/iovs.03-1366","article-title":"Tear secretion induced by selective stimulation of corneal and conjunctival sensory nerve fibers","volume":"45","author":"Acosta","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.sjopt.2013.12.003_b0035","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1542-0124(12)70112-X","article-title":"Nerves and sensations from the eye surface","volume":"2","author":"Belmonte","year":"2004","journal-title":"Ocul Surf"},{"issue":"1","key":"10.1016\/j.sjopt.2013.12.003_b0040","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1076\/ceyr.22.1.8.6977","article-title":"The conjunctival epithelium in dry eye subtypes: effect of preserved and non-preserved topical treatments","volume":"22","author":"Albietz","year":"2001","journal-title":"Curr Eye Res"},{"issue":"11","key":"10.1016\/j.sjopt.2013.12.003_b0450","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/bmt.2012.50","article-title":"Surgical management of lacrimal punctal cauterization in chronic GVHD-related dry eye with recurrent punctal plug extrusion","volume":"47","author":"Yaguchi","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.sjopt.2013.12.003_b0050","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00003226-199603000-00004","article-title":"Effect of periocular humidity on the tear film lipid layer","volume":"15","author":"Korb","year":"1996","journal-title":"Cornea"},{"issue":"2","key":"10.1016\/j.sjopt.2013.12.003_b0455","first-page":"108","article-title":"2007 Report of the international dry eye workshop","volume":"5","author":"Methodologies to diagnose and monitor dry eye disease","year":"2007","journal-title":"Ocul Surf"},{"issue":"5","key":"10.1016\/j.sjopt.2013.12.003_b0060","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/01.ICL.0000162759.79740.46","article-title":"Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface","volume":"31","author":"Luo","year":"2005","journal-title":"Eye Cont Lens"},{"issue":"12","key":"10.1016\/j.sjopt.2013.12.003_b0065","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1167\/iovs.03-1145","article-title":"Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface","volume":"45","author":"Luo","year":"2004","journal-title":"Invest Ophthalmol Vis sci"},{"issue":"8","key":"10.1016\/j.sjopt.2013.12.003_b0070","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1631\/jzus.2006.B0675","article-title":"A clinical study of the efficacy of topical corticosteroids on dry eye","volume":"7","author":"Yang","year":"2006","journal-title":"J Zhejiang Univ Sci B"},{"key":"10.1016\/j.sjopt.2013.12.003_b0075","unstructured":"Bowling E, Russell GE. Topical Steroids and the treatment of dry eye. http:\/\/www.reviewofcontactlenses.com\/content\/d\/dry_eye\/c\/27245\/.2011."},{"key":"10.1016\/j.sjopt.2013.12.003_b0080","unstructured":"Allergan. RESTASIS\u00ae (cyclosporine ophthalmic emulsion) 0.05%. http:\/\/www.allergan.com\/products\/eye_care\/restasis.htm2012."},{"key":"10.1016\/j.sjopt.2013.12.003_b0085","unstructured":"Caceres V. Ocular surface, treating dry eye. http:\/\/www.eyeworld.org\/article-treating-dry-eye2011."},{"key":"10.1016\/j.sjopt.2013.12.003_b0090","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2174\/1874312901206010232","article-title":"JAK kinases in health and disease: an update","volume":"6","author":"Laurence","year":"2012","journal-title":"Open Rheumatol J"},{"issue":"5164","key":"10.1016\/j.sjopt.2013.12.003_b0095","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science (New York, NY)"},{"issue":"5","key":"10.1016\/j.sjopt.2013.12.003_b0100","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1067\/mai.2000.106899","article-title":"Cytokine receptor signaling pathways","volume":"105","author":"Leonard","year":"2000","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.sjopt.2013.12.003_b0105","first-page":"1153","article-title":"Jaks, STATs, cytokines, and sepsis","volume":"9","author":"Scott","year":"2002","journal-title":"Clin Diagn Lab Immunol"},{"issue":"5","key":"10.1016\/j.sjopt.2013.12.003_b0110","first-page":"491","article-title":"CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders","volume":"10","author":"West","year":"2009","journal-title":"Curr Opin Invest Drugs (London, England: 2000)"},{"issue":"3","key":"10.1016\/j.sjopt.2013.12.003_b0115","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ni.1993","article-title":"Fate mapping of IL-17-producing T cells in inflammatory responses","volume":"12","author":"Hirota","year":"2011","journal-title":"Nat Immunol"},{"issue":"7","key":"10.1016\/j.sjopt.2013.12.003_b0120","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3346\/jkms.2011.26.7.938","article-title":"Interleukin-17 in various ocular surface inflammatory diseases","volume":"26","author":"Kang","year":"2011","journal-title":"J Korean Med Sci"},{"issue":"1","key":"10.1016\/j.sjopt.2013.12.003_b0125","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1479-7364-5-1-30","article-title":"Evolutionary divergence and functions of the human interleukin (IL) gene family","volume":"5","author":"Brocker","year":"2010","journal-title":"Hum Genomics"},{"issue":"8","key":"10.1016\/j.sjopt.2013.12.003_b0130","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1167\/iovs.04-1326","article-title":"The controlled-environment chamber: a new mouse model of dry eye","volume":"46","author":"Barabino","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.sjopt.2013.12.003_b0135","unstructured":"Garcia CK, Reddy S, Sieczkiewicz GJ, et al., IL-17 family cytokine compositions and uses, WO\/2011\/0445632011."},{"key":"10.1016\/j.sjopt.2013.12.003_b0140","unstructured":"Adelman BA, Treating surface of the eye disorders. WO\/2011\/1634522011."},{"key":"10.1016\/j.sjopt.2013.12.003_b0145","unstructured":"Kang SW, Cim CH, Composition for prevention or treatment of eye diseases, WO\/2010\/0475002010."},{"key":"10.1016\/j.sjopt.2013.12.003_b0150","unstructured":"MMP9 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase). In: http:\/\/www.ncbi.nlm.nih.gov\/gene?Db=gene&Cmd=ShowDetailView&TermToSearch=4318, editor. National Center for Biotechnology Information (NCBI)2013."},{"issue":"5","key":"10.1016\/j.sjopt.2013.12.003_b0155","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/gene.2012.9","article-title":"Sjogren\u2019s syndrome pathological neovascularization is regulated by VEGF-A-stimulated TACE-dependent crosstalk between VEGFR2 and NF-kappaB","volume":"13","author":"Sisto","year":"2012","journal-title":"Genes Immun"},{"key":"10.1016\/j.sjopt.2013.12.003_b0160","unstructured":"Hong BS, Meadows DL, Methods and compositions for treating dry eye. WO\/2009\/0649832009."},{"issue":"2","key":"10.1016\/j.sjopt.2013.12.003_b0165","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/jop.2005.21.139","article-title":"Preservation of tear film integrity and inhibition of corneal injury by dexamethasone in a rabbit model of lacrimal gland inflammation-induced dry eye","volume":"21","author":"Nagelhout","year":"2005","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.sjopt.2013.12.003_b0170","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/ICU.0b013e32834787bb","article-title":"MMP-9 and the perioperative management of LASIK surgery","volume":"22","author":"Sambursky","year":"2011","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.sjopt.2013.12.003_b0175","unstructured":"Rodgers JD, Shepard S, Li YL, et al., Azetidine and cyclobutane derivatives as JAK inhibitors. WO\/2009\/1145122009."},{"key":"10.1016\/j.sjopt.2013.12.003_b0180","unstructured":"Friedman PA, Friedman JS, Luchi ME, et al., Janus kinase inhibitors for treatment of dry eye and other eye related diseases, US200611637545, WO\/2010\/039939, US201001134162010."},{"key":"10.1016\/j.sjopt.2013.12.003_b0185","unstructured":"Rodgers JD, Shepard S, Azetidine and cyclobutane derivatives as JAK inhibitors, US201281586162012."},{"issue":"3","key":"10.1016\/j.sjopt.2013.12.003_b0190","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0888-7543(88)90003-1","article-title":"Regional localization of the interferon-beta 2\/B-cell stimulatory factor 2\/hepatocyte stimulating factor gene to human chromosome 7p15-p21","volume":"2","author":"Ferguson-Smith","year":"1988","journal-title":"Genomics"},{"key":"10.1016\/j.sjopt.2013.12.003_b0195","unstructured":"Li H, Heckrodt TJ, Chen Y, et al., Compositions and methods for inhibition of the JAK pathway. WO\/2010\/0856842010."},{"key":"10.1016\/j.sjopt.2013.12.003_b0200","unstructured":"Taylor V, Li H, Singh R, Compositions and methods for inhibition of the JAK pathway. WO\/2011\/0171782011."},{"key":"10.1016\/j.sjopt.2013.12.003_b0205","unstructured":"Li H, Heckrodt TJ, Chen Y, et al., Compositions and methods for inhibition of the JAK pathway. WO\/2012\/0159722012."},{"key":"10.1016\/j.sjopt.2013.12.003_b0210","unstructured":"Dana R, Chauhan S, Therapeutic compositions for treatment of ocular inflammatory disorders, WO\/2009\/0890362009."},{"issue":"1","key":"10.1016\/j.sjopt.2013.12.003_b0215","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1084\/jem.177.1.195","article-title":"Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity","volume":"177","author":"Rouvier","year":"1993","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.sjopt.2013.12.003_b0220","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat Rev Drug Dis"},{"key":"10.1016\/j.sjopt.2013.12.003_b0225","unstructured":"Quiniou C, Chemtob S, Barney S, Allosteramers for TNF receptors and uses. WO\/2010\/124259 2010."},{"key":"10.1016\/j.sjopt.2013.12.003_b0230","unstructured":"Kaufmann M, Barney S, Methods of identification of allosteramers. WO\/2010\/1242622010."},{"issue":"9","key":"10.1016\/j.sjopt.2013.12.003_b0235","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/ICO.0b013e3181a16578","article-title":"Analysis of inflammatory cytokines in the tears of dry eye patients","volume":"28","author":"Massingale","year":"2009","journal-title":"Cornea"},{"issue":"6","key":"10.1016\/j.sjopt.2013.12.003_b0240","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/ICO.0b013e31822481c2","article-title":"Topical calcineurin inhibitors in the treatment of steroid-dependent atopic keratoconjunctivitis","volume":"31","author":"Tzu","year":"2012","journal-title":"Cornea"},{"issue":"10","key":"10.1016\/j.sjopt.2013.12.003_b0245","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1517\/13543784.16.10.1525","article-title":"Next-generation calcineurin inhibitors for ophthalmic indications","volume":"16","author":"Anglade","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.sjopt.2013.12.003_b0250","unstructured":"Mitra A, Valagaleti PR, Natesan S, Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors. US2008\/0791702008."},{"issue":"11","key":"10.1016\/j.sjopt.2013.12.003_b0255","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s00347-009-2005-2","article-title":"Sex hormones and dry eye","volume":"106","author":"Schirra","year":"2009","journal-title":"Ophthalmologe"},{"issue":"1","key":"10.1016\/j.sjopt.2013.12.003_b0260","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.exer.2011.12.016","article-title":"Influence of sex hormones and genetic predisposition in Sjogren\u2019s syndrome: a new clue to the immunopathogenesis of dry eye disease","volume":"96","author":"Mostafa","year":"2012","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.sjopt.2013.12.003_b0265","unstructured":"Dalton JT, Miller DD, SARMS and method of use thereof. US201077724332010."},{"key":"10.1016\/j.sjopt.2013.12.003_b0270","unstructured":"Dalton JT, Miller DD, Substituted acylanilides and methods of use thereof. US201180806822011."},{"key":"10.1016\/j.sjopt.2013.12.003_b0275","unstructured":"Dalton JT, Miller DD, Rakov I, et al., Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof. US201181105622011."},{"key":"10.1016\/j.sjopt.2013.12.003_b0280","unstructured":"Dalton JT, Barrett C, He Y, et al., Nuclear receptor binding agents. US201281588282012."},{"key":"10.1016\/j.sjopt.2013.12.003_b0285","unstructured":"Zhi L, Selective androgen receptor modulators (SARMS) and uses thereof, WO\/2009\/082437 2009."},{"key":"10.1016\/j.sjopt.2013.12.003_b0290","unstructured":"Varchi G., Guerrini A., Brigliadori G, et al., Selective androgen receptor modulators (SARMS). WO\/2010\/0925462010."},{"key":"10.1016\/j.sjopt.2013.12.003_b0295","unstructured":"Varchi G, Tesei A, Brigliadori G, Non-steroidal compounds for androgen receptor modulation. WO\/2010\/1163422010."},{"key":"10.1016\/j.sjopt.2013.12.003_b0300","unstructured":"Aberg AKG, inventorTreating xerophthalmia with compounds increasing meibomian gland secretion. R-salbutamol for ocular indications is preferably administered by instillation to the eye or into the conjunctival sac. WO\/2011\/0687862011."},{"key":"10.1016\/j.sjopt.2013.12.003_b0305","unstructured":"Schlienger N, Thygesen MB, Pawlas J, et al., Aminophenyl derivatives as selective androgen receptor modulators. US200975858772009."},{"key":"10.1016\/j.sjopt.2013.12.003_b0310","unstructured":"Ousler III GW, Chapin MJ, Abelson MB, Formulations and methods for treating dry eye. WO\/2008\/1537462008."},{"key":"10.1016\/j.sjopt.2013.12.003_b0315","unstructured":"Uldam HK, Thygesen MB, N-substituted piperidine derivatives as serotonin receptor agents. WO\/2009\/0394612009."},{"key":"10.1016\/j.sjopt.2013.12.003_b0320","unstructured":"Schlienger N, Thygesen M, Uldam HK, et al., N-substituted piperidine derivatives as serotonin receptor agents. WO\/2010\/1113532010."},{"issue":"1","key":"10.1016\/j.sjopt.2013.12.003_b0325","first-page":"3","article-title":"Central serotonin receptors. Principal fundamental and functional aspects. Therapeutic applications","volume":"150","author":"Moulignier","year":"1994","journal-title":"Rev Neurol (Paris)"},{"issue":"4","key":"10.1016\/j.sjopt.2013.12.003_b0330","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1476-5381.1978.tb07758.x","article-title":"Characterization of receptors mediating 5-hydroxytryptamine- and catecholamine-induced platelet aggregation, assessed by the actions of alpha- and beta-blockers, butyrophenones, 5-HT antagonists and chlorpromazine","volume":"62","author":"Boullin","year":"1978","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.sjopt.2013.12.003_b0335","unstructured":"Oh U, Cho HW, Yang YD, et al., Method of identifying agents which modulate the activity of calcium activated chloride channel. WO\/2009\/0514392009."},{"issue":"7","key":"10.1016\/j.sjopt.2013.12.003_b0340","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/archophthalmol.2010.124","article-title":"Evidence of corneal lymphangiogenesis in dry eye disease: a potential link to adaptive immunity?","volume":"128","author":"Goyal","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.sjopt.2013.12.003_b0345","unstructured":"Dana R, Chauhan S, Therapeutic compositions for the treatment of dry eye disease. WO\/2011\/1066972011."},{"issue":"1","key":"10.1016\/j.sjopt.2013.12.003_b0350","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/archophthalmol.2011.266","article-title":"Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease","volume":"130","author":"Goyal","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.sjopt.2013.12.003_b0355","unstructured":"Aberg AKG, Johnson K, Treating xerophthalmia with Norketotifen. WO\/2010\/0476812010."},{"key":"10.1016\/j.sjopt.2013.12.003_b0360","unstructured":"Aberg AKG, Johnson K, Ocular formulations of Norketotifen. WO\/2010\/0598942010."},{"issue":"1","key":"10.1016\/j.sjopt.2013.12.003_b0365","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s13318-012-0080-2","article-title":"Ketotifen is an antimalarial prodrug of norketotifen with blood schizonticidal and liver-stage efficacy","volume":"37","author":"Milner","year":"2012","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.sjopt.2013.12.003_b0370","unstructured":"Ramsden N, Major J, Morel A, et al., Pyrimidine derivatives as ZAP-70 inhibitors. WO\/2010\/1427662010."},{"key":"10.1016\/j.sjopt.2013.12.003_b0375","unstructured":"Major J, Piton N, Sulfonamides and sulfamides as ZAP-70 inhibitors. WO\/2010\/1461322010."},{"key":"10.1016\/j.sjopt.2013.12.003_b0380","unstructured":"Sunose M, Major J, Harrison RJ, et al., Heterocyclylaminopyrimidines as kinase inhibitors. WO\/2010\/1461332010."},{"issue":"2","key":"10.1016\/j.sjopt.2013.12.003_b0385","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00281-010-0196-x","article-title":"ZAP70: a master regulator of adaptive immunity","volume":"32","author":"Fischer","year":"2010","journal-title":"Semin Immunopathol"},{"issue":"4","key":"10.1016\/j.sjopt.2013.12.003_b0390","first-page":"310","article-title":"ZAP-70 and defects of T-cell receptor signaling","volume":"35","author":"Elder","year":"1998","journal-title":"Semin Hematol"},{"issue":"6539","key":"10.1016\/j.sjopt.2013.12.003_b0395","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/376435a0","article-title":"Essential role for ZAP-70 in both positive and negative selection of thymocytes","volume":"376","author":"Negishi","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.sjopt.2013.12.003_b0400","unstructured":"Nakajima T, Nakajima T, Azuma M, Partial peptide of lacritin. WO\/2011\/0342072011."},{"key":"10.1016\/j.sjopt.2013.12.003_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2013.05.020","article-title":"Lacritin and the tear proteome as natural replacement therapy for dry eye","author":"Karnati","year":"2013","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.sjopt.2013.12.003_b0410","unstructured":"Cha S, Pauley KM, Targeted receptor-mediated siRNA. WO\/2012\/0060832012."},{"key":"10.1016\/j.sjopt.2013.12.003_b0415","unstructured":"Michael J. Dart, Philip R. Kym, Eric A. Voight, et al., Trpv1 antagonists. WO20130962262013."},{"issue":"5","key":"10.1016\/j.sjopt.2013.12.003_b0420","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00439-013-1288-1","article-title":"Silencing human genetic diseases with oligonucleotide-based therapies","volume":"132","author":"Martinez","year":"2013","journal-title":"Hum Genet"},{"key":"10.1016\/j.sjopt.2013.12.003_b0425","unstructured":"V. G., J. M-M, S\u00e1daba B., et al., editors. SYL1001 for Treatment of Ocular Discomfort in Dry Eye: Safety and Tolerance (Phase I Study). ARVO 2012; 2012."},{"issue":"11","key":"10.1016\/j.sjopt.2013.12.003_b0430","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1167\/iovs.09-5088","article-title":"Diadenosine polyphosphates in tears of Sjogren syndrome patients","volume":"51","author":"Carracedo","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.sjopt.2013.12.003_b0435","first-page":"129","article-title":"A molecular marker for dry eye","volume":"82","author":"Pintor","year":"2007","journal-title":"Archivos de la Sociedad Espanola de Oftalmologia"},{"issue":"4","key":"10.1016\/j.sjopt.2013.12.003_b0440","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.survophthal.2011.11.003","article-title":"Evaluation of dry eye","volume":"57","author":"McGinnigle","year":"2012","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"10.1016\/j.sjopt.2013.12.003_b0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2010.10.032","article-title":"Tear osmolarity in the diagnosis and management of dry eye disease","volume":"151","author":"Lemp","year":"2011","journal-title":"Am J Ophthalmol"}],"container-title":["Saudi Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319453413001392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319453413001392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T14:48:18Z","timestamp":1597934898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1319453413001392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S1319453413001392"],"URL":"https:\/\/doi.org\/10.1016\/j.sjopt.2013.12.003","relation":{},"ISSN":["1319-4534"],"issn-type":[{"value":"1319-4534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent developments on dry eye disease treatment compounds","name":"articletitle","label":"Article Title"},{"value":"Saudi Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sjopt.2013.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}